Track Longeveron Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Longeveron Inc. LGVN Open Longeveron Inc. in new tab

0.6761 USD
P/E
3.34
EPS
-1.14
P/B
2.84
ROE
-164.75
Beta
-0.32
Target Price
6.82 USD
Longeveron Inc. logo

Longeveron Inc.

🧾 Earnings Recap – Q3 2025

Longeveron reported significant advancements in Q3 2025, including the completion of enrollment in its pivotal HLHS clinical trial and a focused strategy to secure additional financing.

  • Completed enrollment for the ELPIS II pivotal Phase IIb clinical trial, with results expected in Q3 2026, paving the way for potential regulatory approval.
  • Extended cash runway into late Q1 2026 through operational decisions and an at-the-market financing facility, with potential to raise up to $10.7 million if needed.
  • Focus on bolstering BLA preparedness ahead of the ELPIS II data release, with adjusted timelines for full BLA filing anticipated in 2027.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
P/E3.34
EPS-1.14
Book Value0.25
Price to Book2.84
Debt/Equity14.52
% Insiders11.076%
Growth
Revenue Growth-0.40%
Estimates
Forward P/E-0.46
Forward EPS-1.53
Target Mean Price6.82

DCF Valuation

Tweak assumptions to recompute fair value for Longeveron Inc. (LGVN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Longeveron Inc. Logo Longeveron Inc. Analysis (LGVN)

United States Health Care Official Website Stock

Is Longeveron Inc. a good investment? Longeveron Inc. (LGVN) is currently trading at 0.6761 USD. Market analysts have a consensus price target of 6.82 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 3.34. This relatively low multiple may signal that Longeveron Inc. is undervalued compared to historical market norms.

Earnings Schedule: Longeveron Inc. is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -1.53.

Investor FAQ

Does Longeveron Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Longeveron Inc.?

Longeveron Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -1.14.

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Exchange Ticker
NCM (Australia) LGVN

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 27, 2024 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion